-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Antigen-Specific Immunotherapies for Acute Myeloid Leukemia

Program: Education Program
Session: Treatment of Acute Myeloid Leukemia: Moving Beyond 3 + 7
Saturday, December 5, 2015, 2:00 PM-3:30 PM
Hall E2, Level 2 (Orange County Convention Center)
Monday, December 7, 2015, 2:45 PM-4:15 PM
Hall E1, Level 2 (Orange County Convention Center)

Roland B. Walter, MD, PhD, MS

Department of Medicine/Division of Hematology, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

Disclosures: Walter: AstraZeneca, Inc.: Consultancy ; Covagen AG: Consultancy ; Amphivena Therapeutics, Inc.: Consultancy , Research Funding ; Pfizer, Inc.: Consultancy ; Seattle Genetics, Inc.: Research Funding ; Amgen, Inc.: Research Funding .

See more of: Treatment of Acute Myeloid Leukemia: Moving Beyond 3 + 7
See more of: Education Program
<< Previous Presentation | Next Presentation >>